Homepage38I • FRA
add
Intellia Therapeutics Inc
Vorige slotkoers
€ 23,64
Dag-range
€ 23,46 - € 23,95
Jaar-range
€ 18,46 - € 41,84
Beurswaarde
2,51Â mld. USD
Gem. volume
75,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 28,94Â mln. | 129,53% |
Bedrijfskosten | 31,09Â mln. | 13,27% |
Netto inkomsten | -107,44Â mln. | -4,18% |
Netto winstmarge | -371,30 | 54,61% |
Winst per aandeel | -1,12 | 4,27% |
EBITDA | -111,49Â mln. | -1,44% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 791,29Â mln. | -15,24% |
Totale activa | 1,26Â mld. | -11,16% |
Totale passiva | 223,45Â mln. | -1,58% |
Totaal aandelenvermogen | 1,04 mld. | — |
Uitstaande aandelen | 96,48 mln. | — |
Koers-boekwaardeverhouding | 2,20 | — |
Rendement op activa | -22,26% | — |
Rendement op kapitaal | -24,65% | — |
Kasstroom
Nettomutatie in liquide middelen
(USD) | mrt 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -107,44Â mln. | -4,18% |
Operationele kasstroom | -120,66Â mln. | -10,37% |
Kasstroom uit beleggingen | 5,90Â mln. | 104,83% |
Kasstroom uit financiering | 59,99Â mln. | 2.601,13% |
Nettomutatie in liquide middelen | -54,77Â mln. | 76,12% |
Vrije kasstroom | -61,17Â mln. | 16,51% |
Over
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
CEO
Opgericht
2014
Hoofdvestiging
Website
Werknemers
526